- Home
- HTHT vs PCVX Comparison
HTHT vs PCVX Comparison
Compare HTHT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HTHT | PCVX |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 7.0B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTHT | PCVX |
|---|---|---|
| Price | $42.11 | $56.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $56.60 | ★ $88.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $6.71 | N/A |
| P/E Ratio | $30.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.56 | $33.62 |
| 52 Week High | $56.53 | $65.00 |
Technical Indicators
Market Signals| Indicator | HTHT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 40.28 |
| Support Level | $40.37 | $52.18 |
| Resistance Level | $43.50 | $58.77 |
| Average True Range (ATR) | 0.89 | 2.10 |
| MACD | -0.28 | -0.48 |
| Stochastic Oscillator | 10.71 | 21.28 |
Price Performance
Historical ComparisonAbout HTHT H World Group Limited
H World Group Ltd a foremost, fast-growing multi-brand hotel group with international operations. The principal business activities of the Company are to develop and operate leased and owned, manachised and franchised hotels mainly in the PRC or PRC Mainland. The Group has two operating segments which are legacy Huazhu and legacy DH according to the way management intends to evaluate results and allocate resources within the Group. The majority of revenue comes from legacy Huazhu. The company has presence in Greater China and also Outside Greater China.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.